IV BCV for Adenovirus Infections

(ATHENA Trial)

This trial tests a new treatment called brincidofovir (BCV) to assess its safety and tolerability for people with adenovirus (AdV) or cytomegalovirus (CMV) infections. Participants will receive BCV through an IV in varying doses and schedules to determine the most effective method. The trial seeks individuals with significant AdV infection (high levels of the virus in the blood) or CMV who are also in a weakened immune state, making them more susceptible to these viruses. The trial aims to help these patients manage their viral infections more effectively. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinator or your doctor for guidance.

Research has shown that brincidofovir (BCV) is generally safe for people. In one study, patients with adenovirus infections took BCV and showed good tolerance, experiencing no serious side effects. Another study focused on children with adenovirus infections who had stem cell transplants; they also tolerated BCV well, with only a few mild or moderate side effects.

Brincidofovir is unique because it uses a novel approach to tackle adenovirus infections. Unlike the standard antiviral treatments, which often involve oral or topical medications, Brincidofovir is administered intravenously, allowing for a continuous and controlled delivery directly into the bloodstream. This method can enhance the drug's effectiveness by maintaining stable drug levels in the body. Additionally, Brincidofovir's mechanism targets viral DNA polymerase, which is different from many existing treatments, potentially offering a more potent and targeted antiviral action. Researchers are excited about its potential to treat adenovirus infections more effectively and with fewer side effects.

Research has shown that brincidofovir (BCV) may help treat adenovirus (AdV) infections. In this trial, participants will receive different dosages of BCV to evaluate its effectiveness. Studies have found that BCV can lower AdV levels in the blood to undetectable levels in more than half of the patients. In some studies, up to 90% of patients eliminated the virus within four weeks of starting treatment. Importantly, these trials revealed no new safety concerns. This suggests that BCV could be a good option for managing AdV infections, especially in people with weakened immune systems.¹²⁵⁶⁷